The human counterpart of mouse B-1 cells

Annals of the New York Academy of Sciences

Volumn 1362, Issue 1, 2015, Pages 143-152

  Rothstein, Thomas L ^a   Quach, Tam D ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Antibody; B cells; Human; Lymphocytes; Phenotype

Indexed keywords

ANTIBODY;

ANTIGEN PRESENTATION; ARTICLE; B 1 CELL; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL POLARITY; CELL POPULATION; COMMON VARIABLE IMMUNODEFICIENCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MULTIPLE SCLEROSIS; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PLASMABLAST; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PHYSIOLOGY; SPECIES DIFFERENCE; TRENDS;

ANIMALS; B-LYMPHOCYTE SUBSETS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; HUMANS; LYMPHOCYTE ACTIVATION; MICE; SPECIES SPECIFICITY;

EID: 84937588183     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12790     Document Type: Article

References (75)

1. Baumgarth, N. 2011. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat. Rev. Immunol. 11: 34-46.
2. Rothstein, T.L., D.O. Griffin, N.E. Holodick, et al. 2013. Human B-1 cells take the stage. Ann. N. Y. Acad. Sci. 1285: 97-114.
3. Kaveri, S.V., G.J. Silverman & J. Bayry. 2012. Natural IgM in immune equilibrium and harnessing their therapeutic potential. J. Immunol. 188: 939-945.
4. Zhong, X., W. Gao, N. Degauque, et al. 2007. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur. J. Immunol. 37: 2400-2404.
5. Kaku, H., K.F. Cheng, Y. Al-Abed & T.L. Rothstein. 2014. A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production. J. Immunol. 193: 5904-5913.
6. O'Garra, A., R. Chang, N. Go, et al. 1992. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 22: 711-717.
7. Sato, T., S. Ishikawa, K. Akadegawa, et al. 2004. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur. J. Immunol. 34: 3346-3358.
8. + T cells. J. Leukoc. Biol. 91: 526-536.
9. Holodick, N.E., J.R. Tumang & T.L. Rothstein. 2009. Continual signaling is responsible for constitutive ERK phosphorylation in B-1a cells. Mol. Immunol. 46: 329-30360.
10. Sanz, I. & F.E. Lee. 2010. B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6: 326-337.
11. Perosa, F., M. Prete, V. Racanelli & F. Dammacco. 2010. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J. Intern. Med. 267: 260-277.
12. Gupta, I.V. & R.C. Jewell. 2012. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann. N.Y. Acad. Sci. 1263: 43-56.
13. + B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol. Today 10: 364-368.
14. Youinou, P. & Y. Renaudineau. 2011. CD5 expression in B cells from patients with systemic lupus erythematosus. Crit. Rev. Immunol. 31: 31-42.
15. Kasaian, M.T., H. Ikematsu & P. Casali. 1992. Identification and analysis of a novel human surface CD5- B lymphocyte subset producing natural antibodies. J. Immunol. 148: 2690-2702.
16. Sims, G.P., R. Ettinger, Y. Shirota, et al. 2005. Identification and characterization of circulating human transitional B cells. Blood 105: 4390-4398.
17. + pre-naive B cell population. J. Immunol. 182: 4116-4126.
18. + B cells. Blood 73: 202-208.
19. + B cells predominate in peripheral tissues of rabbit. J. Immunol. 149: 3858-3864.
20. Wilson, S.M. & B.N. Wilkie. 2007. B-1 and B-2 B-cells in the pig cannot be differentiated by expression of CD5. Vet. Immunol. Immunopathol. 115: 10-16.
21. -. J. Exp. Med. 208: 67-80.
22. Griffin, D.O. & T.L. Rothstein. 2012. Human B1 cell frequency: isolation and analysis of human B1 cells. Front. Immunol. 3: 122.
23. Jego, G., R. Bataille & C. Pellat-Deceunynck. 2001. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 97: 1817-1822.
24. Medina, F., C. Segundo, A. Campos-Caro, et al. 2002. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 99: 2154-2161.
25. Descatoire, M., J.C. Weill, C.A. Reynaud & S. Weller. 2011. A human equivalent of mouse B-1 cells? J. Exp. Med. 208: 2563-2564.
26. Kraljevic, K., S. Wong & D.A. Fulcher. 2013. Circulating phenotypic B-1 cells are decreased in common variable immunodeficiency and correlate with immunoglobulin M levels. Clin. Exp. Immunol. 171: 278-282.
27. Suchanek, O., R. Sadler, E.A. Bateman, et al. 2012. Immunophenotyping of putative human B1 B cells in healthy controls and common variable immunodeficiency (CVID) patients. Clin. Exp. Immunol. 170: 333-341.
28. Torring, C., C.C. Petersen, L. Bjerg, et al. 2013. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 262: 92-99.
29. - B cells generate antibodies to capsular polysaccharides of Streptococcus pneumoniae. J. Allergy Clin. Immunol. 130: 272-275.
30. -. Vaccine 31: 4632-4640.
31. Fiskesund, R., J. Steen, K. Amara, et al. 2014. Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. J. Immunol. 192: 4551-4559.
32. Wang, J., C. Chen, S. Lau, et al. 2009. CD3-positive large B-cell lymphoma. Am. J. Surg. Pathol. 33: 505-512.
33. Yokose, N., K. Ogata, Y. Sugisaki, et al. 2001. CD20-positive T cell leukemia/lymphoma: case report and review of the literature. Ann. Hematol. 80: 372-375.
34. van Lier, R.A., J. Borst, T.M. Vroom, et al. 1987. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. Immunol. 139: 1589-1596.
35. Mentzer, S.J., E. Remold-O'Donnell, M.A. Crimmins, et al. 1987. Sialophorin, a surface sialoglycoprotein defective in the Wiskott-Aldrich syndrome, is involved in human T lymphocyte proliferation. J. Exp. Med. 165: 1383-1392.
36. + B cells." J. Exp. Med. 208: 2566-2569.
37. + B cells. J Exp Med 208: 2565-2566; author reply 2566-2569.
38. Covens, K., B. Verbinnen, N. Geukens, et al. 2013. Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood 121: 5176-5182.
39. + plasma cells. Haematologica 95: 1016-1020.
40. Jourdan, M., A. Caraux, J. De Vos, et al. 2009. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114: 5173-5181.
41. Jourdan, M., A. Caraux, G. Caron, et al. 2011. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J. Immunol. 187: 3931-3941.
42. Li, W., F. Batliwalla & T.L. Rothstein. 2013. Human B-1 cells are not preplasmablasts: analysis of microarray data and other issues. Blood 122: 3691-3693.
43. Yang, Y., E.E. Ghosn, L.E. Cole, et al. 2012. Antigen-specific memory in B-1a and its relationship to natural immunity. Proc. Natl. Acad. Sci. U.S.A. 109: 5388-5393.
44. Lynch, E.F., P.A. Jones & S.H. Swerdlow. 1995. CD43 and CD5 antibodies define four normal and neoplastic B-cell subsets: a three-color flow cytometric study. Cytometry 22: 223-231.
45. Holodick, N.E., T. Vizconde & T.L. Rothstein. 2014. B-1a cell diversity: nontemplated addition in B-1a cell Ig is determined by progenitor population and developmental location. J. Immunol. 192: 2432-2441.
46. Payne, K.J. & G.M. Crooks. 2007. Immune-cell lineage commitment: translation from mice to humans. Immunity 26: 674-677.
47. Thai, T.H., M.M. Purugganan, D.B. Roth & J.F. Kearney. 2002. Distinct and opposite diversifying activities of terminal transferase splice variants. Nat. Immunol. 3: 457-462.
48. Horowitz, A., D.M. Strauss-Albee, M. Leipold, et al. 2013. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci. Transl. Med. 5: 208ra145.
49. Haas, K.M., J.C. Poe, D.A. Steeber & T.F. Tedder. 2005. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23: 7-18.
50. Kruetzmann, S., M.M. Rosado, H. Weber, et al. 2003. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197: 939-945.
51. Kyaw, T., C. Tay, S. Krishnamurthi, et al. 2011. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ. Res. 109: 830-840.
52. Faria-Neto, J.R., K.Y. Chyu, X. Li, et al. 2006. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189: 83-90.
53. Caligiuri, G., J. Khallou-Laschet, M. Vandaele, et al. 2007. Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. College Cardiol. 50: 540-546.
54. Binder, C.J., S. Horkko, A. Dewan, et al. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9: 736-743.
55. de Faire, U., J. Su, X. Hua, et al. 2010. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J. Autoimmun. 34: 73-79.
56. Gronlund, H., G. Hallmans, J.H. Jansson, et al. 2009. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur. J. Cardiovasc. Prev. Rehabil. 16: 382-386.
57. Su, J., A. Georgiades, R. Wu, et al. 2006. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188: 160-166.
58. Tsimikas, S., E.S. Brilakis, R.J. Lennon, et al. 2007. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J. Lipid Res. 48: 425-433.
59. Vuyyuru, R., H. Liu, T. Manser & K.R. Alugupalli. 2011. Characteristics of Borrelia hermsii infection in human hematopoietic stem cell-engrafted mice mirror those of human relapsing fever. Proc. Natl. Acad. Sci. U.S.A. 108: 20707-20712.
60. Cunningham-Rundles, C. & C. Bodian. 1999. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 92: 34-48.
61. Warnatz, K., A. Denz, R. Drager, et al. 2002. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99: 1544-1551.
62. Brouet, J.C., A. Chedeville, J.P. Fermand & B. Royer. 2000. Study of the B cell memory compartment in common variable immunodeficiency. Eur. J. Immunol. 30: 2516-2520.
63. Piqueras, B., C. Lavenu-Bombled, L. Galicier, et al. 2003. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J. Clin. Immunol. 23: 385-400.
64. Lassmann, H., W. Bruck & C.F. Lucchinetti. 2007. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17: 210-218.
65. Hauser, S.L., E. Waubant, D.L. Arnold, et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358: 676-688.
66. Barun, B. & A. Bar-Or. 2012. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 142: 31-37.
67. Antin, J.H., K.A. Ault, J.M. Rappeport & B.R. Smith. 1987. B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. J. Clin. Invest. 80: 325-332.
68. Drexler, H.G., M.K. Brenner, J.Z. Wimperis, et al. 1987. CD5-positive B cells after T cell depleted bone marrow transplantation. Clin. Exp. Immunol. 68: 662-668.
69. Waddick, K.G. & F.M. Uckun. 1993. CD5 antigen-positive B lymphocytes in human B cell ontogeny during fetal development and after autologous bone marrow transplantation. Exp. Hematol. 21: 791-798.
70. + B cells and B1-like cells following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 19: 988-991.
71. Rodriguez-Zhurbenko, N., D. Martinez, R. Blanco, et al. 2013. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic anti-tumor properties. Eur. J. Immunol. 43: 826-837.
72. Besong-Agbo, D., E. Wolf, F. Jessen, et al. 2013. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80: 169-175.
73. Rosenmann, H., Z. Meiner, V. Geylis, et al. 2006. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci. Lett. 410: 90-93.
74. Weksler, M.E., N. Relkin, R. Turkenich, et al. 2002. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37: 943-948.
75. Musher, D.M., A.J. Chapman, A. Goree, et al. 1986. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154: 245-256.